
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The authors describe a novel approach for assessing method robustness. This article contains online-bonus material and was copublished with Pharmaceutical Technology Europe.
Please refer to the full online version of this article, located
over 16 years ago
Inside USP: USP Reaches 2500 Reference Standardsover 16 years ago
Tracking Solid-Dosage Equipmentover 16 years ago
Inside EDQM: The Role of the Pharmacopeia in a Globalized Worldover 16 years ago
More Questions than Answersover 16 years ago
Stay Current at INTERPHEXover 16 years ago
Unconventional Communicationover 16 years ago
The Effect of Overencapsulation on Disintegration and Dissolutionover 16 years ago
In the Spotlight April 2010over 16 years ago
Report from Asia





